Our Products

RAPIVAB® (peramivir injection)

This BioCryst-discovered drug is used for the treatment of influenza.

In December 2014, RAPIVAB® was approved by the FDA, the first FDA approval of a drug discovered by BioCryst.

RAPIVAB® is indicated for the treatment of acute uncomplicated influenza in patients 6 months and older who have been symptomatic for no more than 2 days.

For additional information, please visit www.RAPIVAB.com, and for full U.S. prescribing information, click here.

RAPIVAB® is a registered trademark of BioCryst Pharmaceuticals, Inc. or its affiliates.